Imunopharm|艺妙生物
@imunopharm
Beijing, Room 316, Building No.1, Block B, No. 80 Xingshikou Road, Haidian District,http://www.imunopharm.com/ Pharmaceutical ManufacturingOverview
About Imunopharm|艺妙生物
Imunopharm is a leading and well-established company in the Cell and Gene Therapy (CGT) sector in China. Founded in 2015, the company is committed to its mission “Make Cancer No Longer Incurable.”
Investor Backing & Key Milestones:
Imunopharm is supported by prominent Chinese and international investors, including Thiel Capital, SHERPA, and Legend Capital etc. To date, the company has completed 10 rounds of strategic financing and holds a CAR-T drug production license, with 7 China INDs, 1 US IND, and 1 China NDA acceptance. Its lead asset, IM19 for DLBCL, received NDA acceptance from China NMPA in 2024, with official approval anticipated in early 2026. Additionally, Imunopharm has entered into an out-licensing agreement for IM19 exceeding CNY 1 Billion with a major domestic pharmaceutical company.
Pipeline & Technology Platforms:
The company maintains a robust global CAR-T pipeline across three core therapeutic areas:
• Hematologic Malignancies
• Solid Tumors
• Autoimmune Diseases
This pipeline is powered by four proprietary technology platforms: In vivo CAR-T/Autologous CAR-T/InstanCART/Universal CAR-T (UCART).
Clinical data from its CAR-T candidates have been repeatedly presented at premier international conferences, including ASCO, ASH, IMS, and ESMO.
Manufacturing & Commercialization Readiness:
Imunopharm operates two state-of-the-art cGMP facilities in BJ and Shandong, ensuring scalable production and cost-effective commercialization.
The company is guided by a visionary and experienced executive team:
• Ting He, Ph.D. (Tsinghua University) – Co-founder, Chairman & CEO
• Xin’an Lu, Ph.D. (THU) – Co-founder, CMO
• Feifei Qi, Ph.D. (THU) – Co-founder, CTO
• Yanping Ding, Ph.D. (THU) – VP, Head of R&D
• Ruina Shi, Ph.D. (PKU) – VP, Manufacturing Operations
• Xiaowen Qi – VP, CMC & Registration Affairs
• Jane Fu (University of Cambridge) – VP, Commercial
Today, Imunopharm stands as a cornerstone enterprise in China's CAR-T therapy landscape.
Investor Backing & Key Milestones:
Imunopharm is supported by prominent Chinese and international investors, including Thiel Capital, SHERPA, and Legend Capital etc. To date, the company has completed 10 rounds of strategic financing and holds a CAR-T drug production license, with 7 China INDs, 1 US IND, and 1 China NDA acceptance. Its lead asset, IM19 for DLBCL, received NDA acceptance from China NMPA in 2024, with official approval anticipated in early 2026. Additionally, Imunopharm has entered into an out-licensing agreement for IM19 exceeding CNY 1 Billion with a major domestic pharmaceutical company.
Pipeline & Technology Platforms:
The company maintains a robust global CAR-T pipeline across three core therapeutic areas:
• Hematologic Malignancies
• Solid Tumors
• Autoimmune Diseases
This pipeline is powered by four proprietary technology platforms: In vivo CAR-T/Autologous CAR-T/InstanCART/Universal CAR-T (UCART).
Clinical data from its CAR-T candidates have been repeatedly presented at premier international conferences, including ASCO, ASH, IMS, and ESMO.
Manufacturing & Commercialization Readiness:
Imunopharm operates two state-of-the-art cGMP facilities in BJ and Shandong, ensuring scalable production and cost-effective commercialization.
The company is guided by a visionary and experienced executive team:
• Ting He, Ph.D. (Tsinghua University) – Co-founder, Chairman & CEO
• Xin’an Lu, Ph.D. (THU) – Co-founder, CMO
• Feifei Qi, Ph.D. (THU) – Co-founder, CTO
• Yanping Ding, Ph.D. (THU) – VP, Head of R&D
• Ruina Shi, Ph.D. (PKU) – VP, Manufacturing Operations
• Xiaowen Qi – VP, CMC & Registration Affairs
• Jane Fu (University of Cambridge) – VP, Commercial
Today, Imunopharm stands as a cornerstone enterprise in China's CAR-T therapy landscape.